Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy

Han, YL; Claessen, BE; Chen, SL; Qiu, CG; Zhou, YJ; Xu, YW; Lin, HL; Chen, JY; Wu, Q; Zhang, RY; Luo, SX; Li, YJ; Zhu, JH; Zhao, XX; Xiang, C; Wang, JA; Xi, S; Tao, JH; Sun, YX; Geng, W; Yi, L; Bian, LY; Goel, R; Sartori, S; Zhang, ZJ; Angiolillo, DJ; Cohen, DJ; Gibson, CM; Kastrati, A; Krucoff, M; Mehta, SR; Ohman, EM; Steg, PG; Liu, YQ; Dangas, G; Sharma, S; Baber, U; Mehran, R

Han, YL (通讯作者),Gen Hosp Northern Theater Command, Dept Cardiol, 83 Wenhua Rd, Shenyang 11016, Liaoning, Peoples R China.;Mehran, R (通讯作者),Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, Ctr Intervent Cardiovasc Res & Clin Trials, One Gustave L Levy Pl,Box 1030, New York, NY 10029 USA.

CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2022; 15 (4):

Abstract

BACKGROUND: The risk/benefit tradeoff of dual antiplatelet therapy after percutaneous coronary intervention may vary in East Asian patients as compare......

Full Text Link